22 completed, 5 active not recruiting, 4 terminated, 3 recruiting. 16 Phase 2, 12 Phase 1, 6 Phase 3, 1 Phase 4.
Follow Oral Azacitidine: new trials by email Literature Review of Oral Azacitidine trials Research Report on Oral Azacitidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality Oral Azacitidine - Acute Myeloid Leukemia | Phase 4 | Recruiting | Virginia Commonwealth University | 12 | 2024-11-07 | 2026-05-29 |
| A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia Oral azacitidine - Acute Myeloid Leukemia | Recruiting | Bristol-Myers Squibb | 154 | 2023-11-15 | 2024-11-06 | |
| Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France Oral azacitidine - Acute Myeloid Leukemia (AML) | Completed | Bristol-Myers Squibb | 112 | 2023-05-23 | 2026-02-12 | |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) Oral Azacitidine, Placebo for Oral Azacitidine - Myelodysplastic Syndromes | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 230 | 2022-12-14 | 2026-02-25 |
| Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Oral Azacitidine - T-Cell Large Granular Lymphocyte Leukemia | Phase 1 / Phase 2 | Active not recruiting | Jonathan Brammer | 11 | 2022-06-29 | 2026-10-21 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission Oral Azacitidine, Placebo - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 19 | 2022-01-17 | 2026-02-11 |
| CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed Nivolumab, Oral Azacitidine - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 33 | 2022-01-03 | 2026-06-03 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy BMS-986345, Duvelisib - Non Hodgkin Lymphoma, Hodgkin Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2021-11-18 | 2025-12-04 |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 170 | 2021-10-08 | 2026-10-02 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-01 |
| Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients CC-486 - MDS, CMML | Phase 2 | Completed | University of Florence | 11 | 2021-03-24 | 2026-05-06 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT Oral azacitidine, Matched placebo - Acute Myeloid Leukemia, Myelodysplasia | Phase 3 | Completed | University of Birmingham | 326 | 2019-06-14 | 2026-08-14 |
| Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma Oral azacitidine, R-ICE - Large B-Cell Diffuse Lymphoma | Phase 1 | Completed | Medical University of South Carolina | 9 | 2019-04-04 | 2024-10-28 |
| Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL Oral azacitidine, Romidepsin, Bendamustine - Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 86 | 2018-11-09 | 2026-04-23 |
| CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma CC-486 Administration, CHOP Administration - Previously Untreated Peripheral T-cell Lymphoma | Phase 2 | Completed | Weill Medical College of Cornell University | 21 | 2018-06-01 | 2023-08-22 |
| Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 Azacitidine, CC-486 - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Completed | Kirby Institute | 40 | 2018-05-18 | 2024-05-28 |
| Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer CC-486, Pembrolizumab - Epithelial Ovarian Cancer | Phase 2 | Terminated | Translational Research in Oncology | 34 | 2016-12-20 | 2022-06-10 |
| A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer Oral CC-486, Romidepsin, MK-3475 - Colorectal Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2016-02-19 | 2025-12-03 |
| A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders CC-486 - Hematologic Neoplasm, Neoplasms | Phase 2 | Completed | Celgene | 5 | 2015-10-22 | 2026-04-02 |
Showing 20 of 35. Sign in to see all of them.
Leukemia, Myeloid, Acute (11) · Myelodysplastic Syndromes (8) · Leukemia, Myelomonocytic, Chronic (4) · Carcinoma, Non-Small-Cell Lung (3) · Lymphoma, Large B-Cell, Diffuse (3) · Neoplasms (3) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Immunoblastic Lymphadenopathy (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Recurrence (2) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1)
Celgene (14) · Bristol-Myers Squibb (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Alliance for Clinical Trials in Oncology (1) · Celgene Corporation (1) · City of Hope Medical Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonathan Brammer (1) · Joseph Tuscano (1) · Kirby Institute (1) · Medical University of South Carolina (1) · National Cancer Institute (NCI) (1) · The Lymphoma Academic Research Organisation (1) · Translational Research in Oncology (1) · University of Birmingham (1)
United States (27) · France (11) · Italy (9) · Spain (9) · Germany (7) · United Kingdom (7) · Canada (6) · Australia (5) · Belgium (5) · Greece (4) · Japan (4) · Poland (4) · South Korea (4) · Czechia (3) · Denmark (3)
Nilofer Azad, MD (2) · Barry Skikne, M.D. (1) · Barry Skikne, M.D., FACP; FCP (SA) (1) · Brian Hess, MD (1) · Charles Craddock (1) · Elizabeth A Brem (1) · Gordan Bray, M.D., Ph.D (1) · Hayder Saeed, MD (1) · Ileana Elias, MD (1) · Jia Ruan, MD, Ph.D (1) · John Pimanda, MD (1)
PMID 26296092, PMID 29764853, PMID 33369355, PMID 33643895, PMID 33764805, PMID 34428285, PMID 34454540, PMID 34686472, PMID 34995344, PMID 35437111, PMID 35960871, PMID 35995702, PMID 36463226, PMID 36796016, PMID 36951156, PMID 37952982, PMID 38796193, PMID 39863139, PMID 42545812
2014 (3), 2023 (1), P30CA033572 (1), P30CA093373 (1), U10CA180821 (1), U10CA180888 (1)